Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
DEX spot volume hits record 24% of CEX volume in July 2026

DEX spot volume hits record 24% of CEX volume in July 2026

CryptobriefingCryptobriefing2026/08/02 15:09

Decentralized exchanges now account for roughly a quarter of all spot trading volume handled by their centralized counterparts. The DEX-to-CEX spot volume ratio hit 24.14% in July 2026, the highest level since tracking began in 2019.

Here’s the thing: this milestone arrived during what was actually a slow month for DEX trading. Absolute spot volume on decentralized platforms fell about 26% month-over-month to approximately $130.77B, marking its lowest point in nearly two years. DEXs are grabbing a bigger slice of a shrinking pie, which makes the ratio even more telling.

Advertisement
window.sevioads = window.sevioads || []; var sevioads_preferences = []; sevioads_preferences[0] = {}; sevioads_preferences[0].zone = "de1434f5-fa9e-44a6-93c3-4c2439763717"; sevioads_preferences[0].adType = "banner"; sevioads_preferences[0].inventoryId = "c5700508-581b-472c-8fdd-a931cdbfc8e1"; sevioads_preferences[0].accountId = "1e47efc1-ec2d-4fca-a8b9-354e249e5095"; sevioads.push(sevioads_preferences);

The numbers behind the shift

For most of 2024, DEX volume hovered below 10% of CEX volume. Then 2025 happened. The ratio started climbing steadily, reaching 13-14% and occasionally spiking as high as 25% during peak periods. July 2026’s 24.14% reading isn’t a one-off spike. It’s the continuation of a trend that’s been building for over a year.

Leading DEX protocols driving this volume include familiar names like Uniswap and PancakeSwap, alongside Aerodrome and newer entrants like Hyperliquid.

Why DEXs keep gaining ground

Three ecosystems are doing the heavy lifting here: Solana, Base, and BNB Chain. Each offers permissionless DEX features that centralized exchanges simply cannot replicate without fundamentally changing their business model.

The biggest advantage is speed to market. When a new token launches, it can be trading on a DEX within minutes. On a centralized exchange, the listing process involves compliance reviews, due diligence, and sometimes weeks of back-and-forth.

What this means for the trading landscape

Several major centralized platforms have started exploring decentralized integrations, essentially trying to bolt on the features that make DEXs attractive while maintaining the compliance framework that institutional clients require.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.